Study of adebrelimab with or without apatinib and chemotherapy before surgery for gastric cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding an immunotherapy drug (adebrelimab) and a targeted therapy (apatinib) to standard chemotherapy helps shrink stomach cancer before surgery. It aims to improve outcomes for people with advanced stomach cancer that cannot be removed or has spread.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have stomach cancer or cancer at the junction of the stomach and esophagus that is HER2-negative and cannot be removed by surgery or has spread.
- You have not had chemotherapy, radiation, targeted therapy, or immunotherapy for advanced disease. If you had prior treatment as adjuvant (after surgery) or neoadjuvant (before surgery), it must have finished at least 6 months ago.
- You have at least one tumor that can be measured on a scan.
- You are physically active and able to care for yourself (ECOG score 0-1).
- Your vital organs (blood, liver, kidneys) are functioning well enough to safely participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of an immunotherapy drug (adebrelimab) plus two chemotherapy drugs (capecitabine and oxaliplatin) for people with stomach cancer or cancer where the stomach meets the esophagus. It aims to see if this combination is safe and effective for patients who have not had prior treatment for advanced disease.
This trial tests a combination of three drugs (adebrelimab, apatinib, and paclitaxel) for people with advanced stomach or gastroesophageal junction cancer that has progressed after immunotherapy. The goal is to see if this combination helps control the cancer longer.
This trial tests a combination of three drugs—adebrelimab (an immunotherapy), fruquintinib (a targeted therapy to cut off blood supply to the tumor), and a chemotherapy (paclitaxel or albumin-bound paclitaxel)—in people with advanced stomach/gastric cancer whose disease has worsened after one prior chemotherapy. The goal is to see if this new mix can help control the cancer.
This trial tests a combination of two targeted drugs (adebrelimab and fruquintinib) plus chemotherapy (paclitaxel or albumin-bound paclitaxel) for people with advanced gastric or gastroesophageal junction cancer whose disease progressed after prior PD-1 antibody treatment. The goal is to see if this new combination can help when standard options have stopped working.
This trial studies whether combining camrelizumab (an immunotherapy) and apatinib (a targeted pill) can control advanced, unresectable stomach or gastroesophageal junction cancer that has grown after first treatment. It also looks at how safe the combination is.
This trial tests a new combination (tislelizumab plus apatinib and chemotherapy) before surgery for certain advanced stomach cancers, compared with the standard chemotherapy plus S1. The goal is to shrink the tumor and improve outcomes before and around surgery.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.